Interleukin Genetics, a developer of genetics-based tests for early detection of periodontal disease and other health conditions, has filed with the U.S. Securities and Exchange Commission to sell up to $75 million in stock and debt, according to a report in the Boston Business Journal.
The company said it may offer shares of its common stock and preferred stock and various series of debt securities and/or warrants, the Journal reported.
The company said it plans to use the offering's proceeds to support its operations and potentially address other financial obligations.
Interleukin had $1.4 million in cash and cash equivalents as of September 30, 2009, compared with $4.9 million as of December 31, 2008.
